Business Description
Caris Life Sciences Inc
NAICS : 541713
SIC : 2833
ISIN : US1421521071
Total Employee Number:
1,846Description
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.91 | |||||
Equity-to-Asset | 0.51 | |||||
Debt-to-Equity | 0.73 | |||||
Debt-to-EBITDA | 3.87 | |||||
Interest Coverage | 1.9 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 3.5 | |||||
Beneish M-Score | -2.33 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 68.5 | |||||
3-Year EPS without NRI Growth Rate | -27.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 20.07 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 30.77 | |||||
9-Day RSI | 33.81 | |||||
14-Day RSI | 38.24 | |||||
3-1 Month Momentum % | -7.56 | |||||
6-1 Month Momentum % | -24.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.05 | |||||
Quick Ratio | 6.52 | |||||
Cash Ratio | 5.72 | |||||
Days Inventory | 68.51 | |||||
Days Sales Outstanding | 28.87 | |||||
Days Payable | 49.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | -12.13 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.72 | |||||
Operating Margin % | 11.94 | |||||
Net Margin % | 3.75 | |||||
EBITDA Margin % | 12.27 | |||||
FCF Margin % | 13.56 | |||||
OCF Margin % | 16.2 | |||||
ROE % | Neg. Equity | |||||
ROA % | 3.76 | |||||
ROIC % | 50.67 | |||||
3-Year ROIIC % | -1825.15 | |||||
ROC (Joel Greenblatt) % | 82.08 | |||||
ROCE % | 11.6 | |||||
Moat Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 124.77 | |||||
PS Ratio | 2.92 | |||||
PB Ratio | 7.4 | |||||
Price-to-Tangible-Book | 7.64 | |||||
Price-to-Free-Cash-Flow | 31.25 | |||||
Price-to-Operating-Cash-Flow | 26.06 | |||||
EV-to-EBIT | 44.06 | |||||
EV-to-Forward-EBIT | 58.27 | |||||
EV-to-EBITDA | 35.9 | |||||
EV-to-Forward-EBITDA | 52.09 | |||||
EV-to-Revenue | 4.41 | |||||
EV-to-Forward-Revenue | 3.96 | |||||
EV-to-FCF | 32.38 | |||||
| Price-to-Net-Current-Asset-Value | 9.86 | |||||
| Price-to-Net-Cash | 17.22 | |||||
Earnings Yield (Greenblatt) % | 2.27 | |||||
FCF Yield % | 2.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Caris Life Sciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 779.13 | ||
| EPS (TTM) (€) | -6.603 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 38.24 | ||
| 14-Day ATR (€) | 0.734857 | ||
| 20-Day SMA (€) | 14.865 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 12.1 - 33.4 | ||
| Shares Outstanding (Mil) | 282.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Caris Life Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Caris Life Sciences Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 103 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 102 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | In 11 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 10 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 10:40 | 14.10 (-4.08%) | ||
| General meeting for 2026 | 2026-06-04 10:00 | 13.30 (-4.32%) | ||
| Guidance call for 2026 | 2026-05-12 10:00 | 13.50 (-0.74%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 16.30 (+1.88%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 16.30 (+1.88%) | ||
| Annual report for 2025 | 2026-03-03 | 17.60 (+4.76%) |
Show
Entries
Caris Life Sciences Inc Frequently Asked Questions
What is Caris Life Sciences Inc(STU:49J)'s stock price today?
The current price of STU:49J is €13.60. The 52 week high of STU:49J is €33.40 and 52 week low is €12.10.
When is next earnings date of Caris Life Sciences Inc(STU:49J)?
The next earnings date of Caris Life Sciences Inc(STU:49J) is 2026-08-05.
Does Caris Life Sciences Inc(STU:49J) pay dividends? If so, how much?
Caris Life Sciences Inc(STU:49J) does not pay dividend.
Press Release
Articles on Caris Life Sciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers